168 related articles for article (PubMed ID: 30214486)
1. Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era.
Kister I; Bacon TE; Cutter GR
Ther Adv Neurol Disord; 2018; 11():1756286418793613. PubMed ID: 30214486
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
3. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
[TBL] [Abstract][Full Text] [Related]
5. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice.
Baldassari LE; Nakamura K; Moss BP; Macaron G; Li H; Weber M; Jones SE; Rao SM; Miller D; Conway DS; Bermel RA; Cohen JA; Ontaneda D; McGinley MP
Mult Scler Relat Disord; 2020 Feb; 38():101525. PubMed ID: 31759186
[TBL] [Abstract][Full Text] [Related]
6. How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity.
Kister I; Bacon T; Cutter GR
Neurol Clin Pract; 2021 Aug; 11(4):335-341. PubMed ID: 34476125
[TBL] [Abstract][Full Text] [Related]
7. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
8. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
9. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
10. New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability.
Weideman AM; Barbour C; Tapia-Maltos MA; Tran T; Jackson K; Kosa P; Komori M; Wichman A; Johnson K; Greenwood M; Bielekova B
Front Neurol; 2017; 8():598. PubMed ID: 29176958
[TBL] [Abstract][Full Text] [Related]
11. Disability in multiple sclerosis: a reference for patients and clinicians.
Kister I; Chamot E; Salter AR; Cutter GR; Bacon TE; Herbert J
Neurology; 2013 Mar; 80(11):1018-24. PubMed ID: 23427319
[TBL] [Abstract][Full Text] [Related]
12. Alternating hemiplegia of childhood: evolution over time and mouse model corroboration.
Uchitel J; Wallace K; Tran L; Abrahamsen T; Hunanyan A; Prange L; Jasien J; Caligiuri L; Pratt M; Rikard B; Fons C; De Grandis E; Vezyroglou A; Heinzen EL; Goldstein DB; Vavassori R; Papadopoulou MT; Cocco I; Moré R; ; ; Arzimanoglou A; Panagiotakaki E; Mikati MA
Brain Commun; 2021; 3(3):fcab128. PubMed ID: 34396101
[TBL] [Abstract][Full Text] [Related]
13. Serum Tumor Necrosis Factor-Alpha Levels Correlate with Cognitive Function Scales Scores in Multiple Sclerosis Patients.
El-Salem K; Al-Mistarehi AH; Hanan Khalil ; Alham Al-Sharman ; Yassin A
Mult Scler Relat Disord; 2021 Jan; 47():102621. PubMed ID: 33197871
[TBL] [Abstract][Full Text] [Related]
14. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
15. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
[TBL] [Abstract][Full Text] [Related]
16. Defining reliable disability outcomes in multiple sclerosis.
Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
[TBL] [Abstract][Full Text] [Related]
17. Brain atrophy and lesion load predict long term disability in multiple sclerosis.
Popescu V; Agosta F; Hulst HE; Sluimer IC; Knol DL; Sormani MP; Enzinger C; Ropele S; Alonso J; Sastre-Garriga J; Rovira A; Montalban X; Bodini B; Ciccarelli O; Khaleeli Z; Chard DT; Matthews L; Palace J; Giorgio A; De Stefano N; Eisele P; Gass A; Polman CH; Uitdehaag BM; Messina MJ; Comi G; Filippi M; Barkhof F; Vrenken H;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1082-91. PubMed ID: 23524331
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Multiple Sclerosis Severity Score in a large US cohort.
Santoro JD; Waltz M; Aaen G; Belman A; Benson L; Gorman M; Goyal MS; Graves JS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rensel M; Rodriguez M; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Hurtubise BF; Roalstad S; Rose J; Casper TC; Chitnis T;
Neurology; 2020 Sep; 95(13):e1844-e1853. PubMed ID: 32690790
[TBL] [Abstract][Full Text] [Related]
19. Retrospective cohort study of the relationship between systolic blood pressure variability and multiple sclerosis disability.
Goldman MD; Min S; Lobo JM; Sohn MW
BMJ Open; 2020 Feb; 10(2):e034355. PubMed ID: 32071184
[TBL] [Abstract][Full Text] [Related]
20. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
